$0.23
(Market cap
$912 Mln
Recently Viewed
Clear AllMarket cap
$912 Mln
Revenue (TTM)
$371 Mln
P/E Ratio
10.1
P/B Ratio
1.3
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
4.2
Debt to Equity
0
Book Value
$10.5
EPS
$1.4
Face value
--
Shares outstanding
63,358,750
CFO
$729.21 Mln
EBITDA
$744.82 Mln
Net Profit
$692.11 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
InMode (INMD)
| -3.4 | 5.9 | -6.2 | -1.6 | -27.5 | -20.2 | -- |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
InMode (INMD)
| -12.0 | -37.7 | -49.4 | 197.3 | 21.1 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
InMode (INMD)
|
14.2 | 912.4 | 370.5 | 93.8 | 27.9 | 13.5 | 10.1 | 1.3 |
| 0.3 | 22.8 | 3.4 | -15.1 | -446.7 | -188.8 | -- | 2.5 | |
| 1.7 | 120.7 | 13.0 | -75.0 | -455.2 | -45.6 | -- | 0.9 |
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe,... Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel. Read more
Chief Financial Officer
Mr. Yair Malca
Chief Financial Officer
Mr. Yair Malca
Headquarters
Yokne'am
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of InMode Ltd (INMD) is $14.19 (NASDAQ) as of 30-Apr-2026 11:41 EDT. InMode Ltd (INMD) has given a return of -27.52% in the last 3 years.
The P/E ratio of InMode Ltd (INMD) is 10.07 times as on 24-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
10.18
|
1.40
|
|
2024
|
7.46
|
1.92
|
|
2023
|
9.66
|
2.43
|
|
2022
|
18.79
|
5.47
|
|
2021
|
36.79
|
14.60
|
The 52-week high and low of InMode Ltd (INMD) are Rs 16.74 and Rs 12.72 as of 30-Apr-2026.
InMode Ltd (INMD) has a market capitalisation of $ 912 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in InMode Ltd (INMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.